What development phase is Raunormin in?

Raunormin is FDA-approved (marketed).

What is the generic name of Raunormin?

DESERPIDINE is the generic (nonproprietary) name of Raunormin.

Last reviewed 2026-04-20 · How we verify

Raunormin (DESERPIDINE)

FDA-approved approved Small molecule Quality 20/100

Raunormin (Deserpidine) is a catecholamine-depleting sympatholytic small molecule originally developed by and currently owned by a pharmaceutical company. It targets the synaptic vesicular amine transporter, leading to a decrease in catecholamine levels in the synaptic cleft. Deserpidine was FDA-approved in 1957 for the treatment of hypertension and angina pectoris. Due to its off-patent status, there are currently no generic manufacturers. Key safety considerations include its potential to cause orthostatic hypotension and other cardiovascular side effects.

At a glance

Generic name	DESERPIDINE
Drug class	Catecholamine-depleting Sympatholytic
Target	Synaptic vesicular amine transporter
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1957

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Raunormin CI brief — competitive landscape report
Raunormin updates RSS · CI watch RSS